Nuvalent Stock (NASDAQ:NUVL)
Previous Close
$89.22
52W Range
$55.33 - $113.51
50D Avg
$95.89
200D Avg
$80.69
Market Cap
$6.25B
Avg Vol (3M)
$515.12K
Beta
1.29
Div Yield
-
NUVL Company Profile
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Performance
Peer Comparison
Ticker | Company |
---|---|
DICE | DICE Therapeutics, Inc. |
CGEM | Cullinan Oncology, Inc. |
KNSA | Kiniksa Pharmaceuticals, Ltd. |
VRDN | Viridian Therapeutics, Inc. |
VTYX | Ventyx Biosciences, Inc. |
CERE | Cerevel Therapeutics Holdings, Inc. |
TVTX | Travere Therapeutics, Inc. |
REPL | Replimune Group, Inc. |
ASND | Ascendis Pharma A/S |
ACLX | Arcellx, Inc. |
GPCR | Structure Therapeutics Inc. |
PCVX | Vaxcyte, Inc. |
UTHR | United Therapeutics Corporation |